A Nationwide, Multi-institutional Retrospective Study of Efficacy and Safety of Eribulin in Korean Breast Cancer Patients
Phase of Trial: Phase IV
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Eisai Korea
- 24 Jan 2019 Status changed from recruiting to completed.
- 20 Jun 2018 Planned End Date changed from 1 Jun 2018 to 1 Jul 2018.
- 20 Jun 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jul 2018.